iStopMM Trial in Iceland #myeloma | Jón Þórir Óskarsson, MSc | ASH 2023

Impact of Financial Toxicity and Time Toxicity in Myeloma QOL | Rahul Banerjee, MD, FACP | ASH 2023

Real-World Bortezomib Patterns in Newly Diagnosed Myeloma | Gurbakhash Kaur, MD, MA | ASH 2023

Fine Particulate Matter and Myeloma Outcomes in Urban Cohort | Michael Wysota, MD | ASH 2023

Genomic Profiling in High-Risk Smoldering Myeloma | Benjamin Diamond, MD | ASH 2023

Dexamethasone Dose Strength Impact in Newly Diagnosed Myeloma | Rahul Banerjee, MD, FACP | ASH 2023

CAR-T in Myeloma Patients with Extramedullary and Paramedullary Disease | Darren Pan, MD | ASH 2023

Real-World Patient Profile and Dosing of Teclistamab in Myeloma | Carlyn Rose Tan, MD | ASH 2023

Updates to Wearable Tech and Early Detection of CRS in Patients | Sridevi Rajeeve, MD | ASH 2023

Real-World Results from Talquetamab and Bispecific Antibodies | Carolina Schinke, MD | ASH 2023

Cost per Responder Analysis of Multiple Myeloma Patients | Doris K Hansen, MD | ASH 2023

Links to Early Responses in Multiple Myeloma Patients | Doris K Hansen, MD | ASH 2023

Comparisons in Time to Next Treatment in Myeloma Patients | Doris K Hansen, MD | ASH 2023